The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study.
Yung-Jue Bang
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Seock-Ah Im
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Keun-Wook Lee
No relevant relationships to disclose
Jae Yong Cho
No relevant relationships to disclose
Eun-Kee Song
No relevant relationships to disclose
Kyung Hee Lee
No relevant relationships to disclose
Yeul Hong Kim
No relevant relationships to disclose
Joon Oh Park
No relevant relationships to disclose
Hoo Geun Chun
No relevant relationships to disclose
Dae Young Zang
No relevant relationships to disclose
Anitra Fielding
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Jacqui Rowbottom
Employment or Leadership Position - AstraZeneca
Woo Ho Kim
No relevant relationships to disclose